U.S. Software Stock News

NasdaqGS:SGRY
NasdaqGS:SGRYHealthcare

Is Surgery Partners Mispriced After 42.3% Five Year Slide and Outpatient Expansion?

If you are wondering whether Surgery Partners is a quietly mispriced opportunity or a value trap in the making, you are not alone. That is exactly what we are going to unpack here. The stock is down 4.9% over the last week and 22.4% year to date, but a 5.0% gain over the past month hints that sentiment may be starting to shift after a long 5 year slide of 42.3%. Recent headlines have focused on Surgery Partners expanding its network of ambulatory surgery centers and deepening relationships...
NYSE:CIVI
NYSE:CIVIOil and Gas

Is Civitas Resources a 2025 Bargain After a 36% Slide and Strong Cash Flow Outlook?

Wondering whether Civitas Resources is a value play or a value trap at today’s price? You are not alone. This stock has quietly shifted from market favorite to contrarian idea. The share price has bounced about 10.5% over the last month but is still down roughly 36.4% year to date and 33.8% over the last year, a mix that often signals either a looming problem or a mispriced opportunity. Recent headlines around Civitas have focused on its portfolio positioning and capital discipline in a...
NasdaqGS:MGPI
NasdaqGS:MGPIBeverage

MGP Ingredients (MGPI): Reassessing Valuation After Chairman’s Share Sale and Ongoing Margin Pressures

After the Chairman of the Board moved to sell a sizable block of shares, MGP Ingredients (MGPI) quickly drew fresh scrutiny as investors weighed this signal against already weakening sales and margin pressure. See our latest analysis for MGP Ingredients. The share sale comes after a rough stretch, with the share price down sharply on a year to date basis and multi year total shareholder returns deeply negative. However, this week’s double digit 7 day share price return hints at traders...
NasdaqGS:HSII
NasdaqGS:HSIIProfessional Services

Heidrick & Struggles Valuation After 2025 Share Price Surge and Pending Cash Buyout Deal

If you are wondering whether Heidrick & Struggles International is still a smart buy after such a strong run, you are not alone. This is exactly what we are going to unpack here. The stock has climbed 33.9% year to date and is up 30.4% over the last year, while longer term holders have seen gains of 108.8% over 3 years and 122.8% over 5 years, all from a recent close of $59.01. Those gains have come as investors have warmed to the company’s positioning in higher value advisory and leadership...
NYSE:QXO
NYSE:QXOTrade Distributors

Three Stocks That May Be Priced Below Their Estimated Worth In December 2025

As the U.S. market navigates a complex landscape with the Dow Jones Industrial Average reaching new heights and tech-heavy indices like the Nasdaq and S&P 500 experiencing pullbacks, investors are closely watching for opportunities amid fluctuating interest rates and economic data. In this environment, identifying stocks that may be undervalued requires careful consideration of their intrinsic worth relative to current market conditions, offering potential value in a diverse portfolio.
NasdaqGS:TMCI
NasdaqGS:TMCIMedical Equipment

Talkspace Leads These 3 Promising Penny Stocks

The U.S. stock market has been experiencing mixed movements, with the Dow Jones Industrial Average recently setting a new all-time high while the Nasdaq and S&P 500 have pulled back due to concerns over tech stocks. Despite these fluctuations, certain investment opportunities continue to capture attention, particularly in areas that offer affordability and potential growth. Penny stocks, though an outdated term, still represent smaller or newer companies that can provide significant value...
NYSE:NGVT
NYSE:NGVTChemicals

Has Ingevity’s 48.8% Rally in 2025 Outpaced Its Fundamental Recovery?

Wondering if Ingevity at around $58.83 is still a smart buy or if the easy money has already been made? You are not alone; this stock has quietly been drawing fresh attention from value focused investors. After a tough few years, the share price has surged, up 12.6% over the last week, 18.8% over the past month, and 48.8% year to date, even though the 3 and 5 year returns are still down 15.5% and 19.7% respectively. Part of this turnaround story reflects shifting sentiment around specialty...